PHILIP BROSHEARS: Open Payments
NPI 1215138920 · EVANSVILLE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,697 in 108 payments from 24 companies in 2025. Trend: 2023 $1,436 · 2024 $1,754 · 2025 $1,697
Food & beverage: $1,697
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $300 |
| Novo Nordisk Inc | 18 | $254 |
| Otsuka America Pharmaceutical, Inc. | 8 | $149 |
| Amgen Inc. | 11 | $141 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $128 |
| PFIZER INC. | 7 | $125 |
| Corium, LLC | 6 | $90 |
| GlaxoSmithKline, LLC. | 5 | $77 |
| Viatris Specialty LLC | 2 | $56 |
| Novartis Pharmaceuticals Corporation | 3 | $48 |
Products named: Ozempic, REXULTI, CAPLYTA, QULIPTA, OTEZLA, UBRELVY, VRAYLAR, Azstarys.
Industry payments across IN — which companies pay providers there.
